source
- Expedition Therapeutics raises $115M Series B to fund phase 2 COPD trial of DPP1 inhibitorExpedition Therapeutics, backed by Sanofi, announced a $115 million Series B financing round. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, and existing i…
- Lisata cuts 72% of workforce and sues Kuva after merger collapseLisata, a solid tumor biotech, announced it is laying off roughly 72% of its employees, including its chief medical officer, as it reassesses its future. The cuts follow the collapse of a planned…